Dashboard
Manage Tickers

KROS Keros Therapeutics, Inc.

Nasdaq kerostx.com


$ 16.24 $ 0.03 (0.19 %)    

Friday, 07-Nov-2025 16:01:46 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 16.2
$ 16.24
$ 15.00 x 200
$ 16.75 x 25
$ 15.89 - $ 16.75
$ 9.12 - $ 72.37
1,327,824
na
493.55M
$ 0.99
$ 7.66
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-26-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-03-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-09-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-25-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-22-2020 03-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wedbush-maintains-neutral-on-keros-therapeutics-raises-price-target-to-16
Wedbush Maintains Neutral on Keros Therape...
11/06/2025 13:35:19

Wedbush analyst Yun Zhong maintains Keros Therapeutics (NASDAQ:KROS) with a Neutral and raises the price target from $15 to ...

keros-therapeutics-q3-eps-018-beats-105-estimate-sales-14262m-beat-3800m-estimate
Keros Therapeutics Q3 EPS $(0.18) Beats $(...
11/05/2025 22:04:17

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(...

keros-therapeutics-announced-that-it-has-commenced-a-cash-tender-offer-to-repurchase-up-to-1944m-of-shares-of-the-companys-common-stock-at-a-purchase-price-of-1775-per-share
Keros Therapeutics Announced That It Has C...
10/20/2025 10:04:41

keros-therapeutics-plans-to-commence-tender-offer-to-repurchase-up-to-194m-of-additional-shares-at-1775shr-in-cash
Keros Therapeutics Plans To Commence Tende...
10/15/2025 10:36:12

keros-therapeutics-to-repurchase-181m-in-shares-from-adar1-and-pontifax-under-375m-capital-return-plan-deal-set-to-close-october-15
Keros Therapeutics To Repurchase $181M In ...
10/15/2025 10:34:39

keros-therapeutics-highlights-presentation-of-ker-065-data-at-american-society-of-bone-and-mineral-research-2025-annual-meeting-on-sept-6
Keros Therapeutics Highlights Presentation...
09/08/2025 12:05:02

adar1-capital-urges-keros-therapeutics-board-to-engage-on-strategy-and-capital-return-warns-of-potential-board-changes
ADAR1 Capital Urges Keros Therapeutics Boa...
08/21/2025 12:36:12

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros...

keros-therapeutics-reveals-the-fda-granted-orphan-drug-designation-for-ker-065-for-the-treatment-of-duchenne-muscular-dystrophy
Keros Therapeutics Reveals The FDA Granted...
08/20/2025 13:50:54

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage ...

hc-wainwright--co-maintains-buy-on-keros-therapeutics-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on Keros...
08/08/2025 10:53:57

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Keros Therapeutics (NASDAQ:KROS) with a Buy and lowers the pri...

keros-therapeutics-announces-strategic-realignment-to-reallocate-resources-towards-development-of-its-key-clinical-program-ker-065-discontinues-development-of-cibotercept-ker-012
Keros Therapeutics Announces Strategic Rea...
08/06/2025 20:59:55

Company Discontinuing Development of Cibotercept (KER-012)Announces Board and Leadership Changes Designed to Support Streamline...

keros-therapeutics-q2-eps-076-beats-111-estimate-sales-18168m-beat-2767m-estimate
Keros Therapeutics Q2 EPS $(0.76) Beats $(...
08/06/2025 20:45:48

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(...

keros-therapeutics-announces-first-patient-dosed-in-phase-3-renew-clinical-trial-of-elritercept-in-adults-with-transfusion-dependent-anemia-with-very-low-low-or-intermediate-risk-mds
Keros Therapeutics Announces First Patient...
07/17/2025 12:16:08

Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and ...

keros-therapeutics-quiet-near-term-outlook-overshadows-pipeline-potential-analyst
Keros Therapeutics' Quiet Near-Term Outloo...
06/10/2025 18:37:27

BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor c...

b-of-a-securities-downgrades-keros-therapeutics-to-neutral-lowers-price-target-to-18
B of A Securities Downgrades Keros Therape...
06/10/2025 12:56:50

B of A Securities analyst Jason Zemansky downgrades Keros Therapeutics (NASDAQ:KROS) from Buy to Neutral and lowers the pric...

keros-therapeutics-board-determines-to-initiate-process-to-return-375m-of-excess-capital-to-stockholders
Keros Therapeutics Board Determines To Ini...
06/09/2025 10:56:45

Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company f...

wedbush-reiterates-neutral-on-keros-therapeutics-maintains-15-price-target
Wedbush Reiterates Neutral on Keros Therap...
05/30/2025 13:24:18

Wedbush analyst Yun Zhong reiterates Keros Therapeutics (NASDAQ:KROS) with a Neutral and maintains $15 price target.

keros-therapeutics-stops-pah-drug-development-shrinks-workforce-by-45
Keros Therapeutics Stops PAH Drug Developm...
05/29/2025 16:54:09

Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of...

keros-discontinues-cibotercept-development-in-pah-after-tropos-trial-safety-and-efficacy-analysis
Keros Discontinues Cibotercept Development...
05/29/2025 11:01:38

keros-therapeutics-to-cut-workforce-by-45-following-cibotercept-discontinuation-expects-17m-annual-savings
Keros Therapeutics To Cut Workforce By 45%...
05/29/2025 10:58:50

Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceut...

keros-therapeutics-reports-topline-data-from-tropos-trial-phase-2-clinical-trial-of-cibotercept-in-combination-with-background-therapy-in-pah-patients
Keros Therapeutics Reports Topline Data Fr...
05/29/2025 10:57:15

Discontinues Development of Cibotercept in PAHAnnounces Corporate Restructuring to Align Operations with Ongoing Strategic Prio...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION